Tag : SHORT-ACTING BETA2-AGONIST

  • CONFERENCE UPDATE
    From SABA reliance to ICS-first: Malaysia’s 2024 CPG ushers in a new era of asthma control

    Malaysia’s 2024 Asthma Clinical Practice Guidelines (CPG) moves beyond short-acting β2-agonist (SABA)-only treatment, introducing inhaled corticosteroid (ICS)-based regimens from the earliest steps, phenotype/endotype-driven biologic algorithms, and system-level reforms to advance personalized asthma care

    doctor name

    Dr. Andrea Ban Yu Lin

    Associate Professor, Senior Consultant Physician and Pulmonologist, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia (HCTM-UKM), Kuala Lumpur, Malaysia